Clinical Trial Update: Enzalutamide With Ribociclib in Treating Patients With Metastatic Castrate-Resistant, Chemotherapy Naive Prostate Cancer That Retains Retinoblastoma Expression [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1/2 trial evaluating enzalutamide in combination with ribociclib in metastatic castration-resistant prostate cancer retaining retinoblastoma expression …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Castration-resistant Prostate Cancer
• Prostate Cancer

Drugs mentioned

• KISQALI (ribociclib)
• Xtandi (enzalutamide)

Snippet

Sponsor: Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University | Conditions: Castration-Resistant Prostate Carcinoma, Metastatic Prostate Carcinoma | Phase 1, Phase 2 | Status: TERMINATED | Results posted: 2026-04-22